Current trends in the use of liposomes for tumor targeting.

The use of liposomes for drug delivery began early in the history of pharmaceutical nanocarriers. These nanosized, lipid bilayered vesicles have become popular as drug delivery systems owing to their efficiency, biocompatibility, nonimmunogenicity, enhanced solubility of chemotherapeutic agents and their ability to encapsulate a wide array of drugs. Passive and ligand-mediated active targeting promote tumor specificity with diminished adverse off-target effects. The current field of liposomes focuses on both clinical and diagnostic applications. Recent efforts have concentrated on the development of multifunctional liposomes that target cells and cellular organelles with a single delivery system. This review discusses the recent advances in liposome research in tumor targeting.

[1]  S. Naylor,et al.  Human transferrin: cDNA characterization and chromosomal localization. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[2]  M. Newman,et al.  Comparative pharmacokinetics, tissue distribution, and therapeutic effectiveness of cisplatin encapsulated in long-circulating, pegylated liposomes (SPI-077) in tumor-bearing mice , 1999, Cancer Chemotherapy and Pharmacology.

[3]  H. Kantarjian,et al.  Liposomal vincristine in relapsed non-Hodgkin's lymphomas: early results of an ongoing phase II trial. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  V. Torchilin,et al.  Drug targeting. , 2000, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[5]  G. Batist,et al.  Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  T. Allen.  Ligand-targeted therapeutics in anticancer therapy , 2002, Nature Reviews Cancer.

[7]  G. Hortobagyi,et al.  Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer , 2002, Cancer Chemotherapy and Pharmacology.

[8]  M. Simionescu,et al.  Designing of ‘intelligent’ liposomes for efficient delivery of drugs , 2002, Journal of cellular and molecular medicine.

[9]  John W. Park.  Liposome-based drug delivery in breast cancer treatment , 2002, Breast Cancer Research.

[10]  D. Carbonaro,et al.  Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation. , 2005, Anticancer research.

[11]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[12]  C. Mamot,et al.  Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. , 2005, Cancer research.

[13]  K. Edwards,et al.  Optimization and characterization of a sphingomyelin/cholesterol liposome formulation of vinorelbine with promising antitumor activity. , 2005, Journal of pharmaceutical sciences.

[14]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[15]  Volkmar Weissig,et al.  Liposomes and Liposome-like Vesicles for Drug and DNA Delivery to Mitochondria , 2006, Journal of liposome research.

[16]  Ű. Langel,et al.  Cell-penetrating peptides as vectors for peptide, protein and oligonucleotide delivery. , 2006, Current opinion in pharmacology.

[17]  M. Yen,et al.  Pegylated liposomal doxorubicin (Lipo-Dox) for platinum-resistant or refractory epithelial ovarian carcinoma: a Taiwanese gynecologic oncology group study with long-term follow-up. , 2006, Gynecologic oncology.

[18]  Vladimir P Torchilin,et al.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[19]  D. Dittmer,et al.  Liposomal daunorubicin as treatment for Kaposi’s sarcoma , 2007, International journal of nanomedicine.

[20]  M. Bally,et al.  Modulation of cancer cell survival pathways using multivalent liposomal therapeutic antibody constructs , 2007, Molecular Cancer Therapeutics.

[21]  Paul C. Wang,et al.  Alexa Fluor 680-labeled transferrin-cationic (NBD-labeled DOPE-DOTAP) liposome-encapsulated gadopentetate dimeglumine complex , 2007 .

[22]  H. Harashima,et al.  Tumor targeting of doxorubicin by anti-MT1-MMP antibody-modified PEG liposomes. , 2007, International journal of pharmaceutics.

[23]  F. Giles,et al.  Treatment of acute lymphoblastic leukaemia : a new era. , 2007, Drugs.

[24]  G. Bendas,et al.  VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. , 2008, Biochimica et biophysica acta.

[25]  S. Futaki,et al.  An artificial virus-like nano carrier system: enhanced endosomal escape of nanoparticles via synergistic action of pH-sensitive fusogenic peptide derivatives , 2008, Analytical and bioanalytical chemistry.

[26]  Robert J. Lee,et al.  Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. , 2008, International journal of pharmaceutics.

[27]  V. Torchilin,et al.  Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. , 2008, Nano letters.

[28]  K. Kono,et al.  Effect of transferrin as a ligand of pH-sensitive fusogenic liposome-lipoplex hybrid complexes. , 2008, Bioconjugate chemistry.

[29]  Jörg Huwyler,et al.  Tumor targeting using liposomal antineoplastic drugs , 2008, International journal of nanomedicine.

[30]  E. Frenkel,et al.  Nanoparticles for drug delivery in cancer treatment. , 2008, Urologic oncology.

[31]  Philip S Low,et al.  Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. , 2008, Accounts of chemical research.

[32]  P. Nelson,et al.  TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis , 2009, Cancer Immunology, Immunotherapy.

[33]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[34]  Leaf Huang,et al.  Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[35]  W. Davros,et al.  Imaging characteristics of zinc sulfide shell, cadmium telluride core quantum dots. , 2008, Nanomedicine.

[36]  N. Plesnila,et al.  Tf-lipoplexes for neuronal siRNA delivery: a promising system to mediate gene silencing in the CNS. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[37]  Sunita Yadav,et al.  Multi-functional nanocarriers to overcome tumor drug resistance. , 2008, Cancer treatment reviews.

[38]  N. Oku,et al.  Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. , 2008, International journal of pharmaceutics.

[39]  V. Torchilin.  Targeted pharmaceutical nanocarriers for cancer therapy and imaging , 2007, The AAPS Journal.

[40]  A. Ullrich,et al.  Paul Ehrlich's magic bullet concept: 100 years of progress , 2008, Nature Reviews Cancer.

[41]  S. Miyatake,et al.  Disposition of TF-PEG-Liposome-BSH in tumor-bearing mice. , 2009, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[42]  Yi Lu,et al.  Reversible cell-specific drug delivery with aptamer-functionalized liposomes. , 2009, Angewandte Chemie.

[43]  Q. Ping,et al.  Targeted delivery of doxorubicin using stealth liposomes modified with transferrin. , 2009, International journal of pharmaceutics.

[44]  Vladimir Torchilin,et al.  Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[45]  R. MacGillivray,et al.  Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[46]  Han-Chung Wu,et al.  Antiangiogenic Targeting Liposomes Increase Therapeutic Efficacy for Solid Tumors* , 2009, Journal of Biological Chemistry.

[47]  R. Gascoyne,et al.  Vincristine sulfate liposomes injection (Marqibo) in heavily pretreated patients with refractory aggressive non‐Hodgkin lymphoma , 2009, Cancer.

[48]  Robert K Prud'homme,et al.  Multifunctional nanoparticles for imaging, delivery and targeting in cancer therapy , 2009, Expert opinion on drug delivery.

[49]  Benedict Law,et al.  Release of liposomal contents by cell-secreted matrix metalloproteinase-9. , 2009, Bioconjugate chemistry.

[50]  Ashish Garg,et al.  Targeting colon cancer cells using PEGylated liposomes modified with a fibronectin-mimetic peptide. , 2008, International journal of pharmaceutics.

[51]  M. Jäättelä,et al.  Lysosomal involvement in cell death and cancer. , 2009, Biochimica et biophysica acta.

[52]  K. Yuen,et al.  Oral bioavailability enhancement of a hydrophilic drug delivered via folic acid-coupled liposomes in rats. , 2009, The Journal of pharmacy and pharmacology.

[53]  H. Shmeeda,et al.  Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[54]  Albert Wong.  Modified Epidermal Growth Factor Receptor (EGFR)-Bearing Liposomes (MRBLs) Are Sensitive to EGF in Solution , 2009, PloS one.

[55]  He Zhang,et al.  Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. , 2009, International journal of pharmaceutics.

[56]  Qian Zhang,et al.  A clinical study on the premedication of paclitaxel liposome in the treatment of solid tumors. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[57]  Vladimir P Torchilin,et al.  Passive and active drug targeting: drug delivery to tumors as an example. , 2010, Handbook of experimental pharmacology.

[58]  Valentina Cauda,et al.  Colchicine-loaded lipid bilayer-coated 50 nm mesoporous nanoparticles efficiently induce microtubule depolymerization upon cell uptake. , 2010, Nano letters.

[59]  Vladimir P Torchilin,et al.  Current trends in liposome research. , 2010, Methods in molecular biology.

[60]  H. Hochster,et al.  Phase II study of liposomal cisplatin (SPI-77) in platinum-sensitive recurrences of ovarian cancer. , 2010, Anticancer research.

[61]  Véronique Préat,et al.  To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[62]  R. Dwek,et al.  Uptake and trafficking of liposomes to the endoplasmic reticulum , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[63]  M. Dewhirst,et al.  Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours , 2010, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[64]  Vladimir P. Torchilin,et al.  Liposomes as ‘smart’ pharmaceutical nanocarriers , 2010 .

[65]  V. Torchilin,et al.  Environment-responsive multifunctional liposomes. , 2010, Methods in molecular biology.

[66]  E. Morselli,et al.  Mitochondrial gateways to cancer. , 2010, Molecular aspects of medicine.

[67]  Yan Zhang,et al.  Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[68]  Bo Yu,et al.  A transferrin receptor-targeted liposomal formulation for docetaxel. , 2010, Journal of nanoscience and nanotechnology.

[69]  H. Shmeeda,et al.  Delivery of zoledronic acid encapsulated in folate-targeted liposome results in potent in vitro cytotoxic activity on tumor cells. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[70]  A. Baeumner,et al.  Aptamer sandwich assays: human α-thrombin detection using liposome enhancement , 2010, Analytical and bioanalytical chemistry.

[71]  Weihong Tan,et al.  A liposome-based nanostructure for aptamer directed delivery. , 2010, Chemical communications.

[72]  L. Mayer,et al.  Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo , 2010, Expert opinion on drug delivery.

[73]  P. Low,et al.  Targeting of nanoparticles: folate receptor. , 2010, Methods in molecular biology.

[74]  S. Simões,et al.  Physicochemical properties of transferrin-associated lipopolyplexes and their role in biological activity. , 2010, Colloids and surfaces. B, Biointerfaces.

[75]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[76]  Juewen Liu,et al.  Stimuli-responsive releasing of gold nanoparticles and liposomes from aptamer-functionalized hydrogels , 2011, Nanotechnology.

[77]  H. Harashima,et al.  Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[78]  M. Ferrari,et al.  Thioaptamer Conjugated Liposomes for Tumor Vasculature Targeting , 2010, Oncotarget.

[79]  Viness Pillay,et al.  A Review on Composite Liposomal Technologies for Specialized Drug Delivery , 2011, Journal of drug delivery.

[80]  Y. Liu,et al.  Synthesis and evaluation of a novel lipophilic folate receptor targeting ligand. , 2011, Anticancer research.

[81]  N. Borys,et al.  Lyso-thermosensitive liposomal doxorubicin: an adjuvant to increase the cure rate of radiofrequency ablation in liver cancer. , 2011, Future oncology.

[82]  Vladimir Torchilin,et al.  Tumor delivery of macromolecular drugs based on the EPR effect. , 2011, Advanced drug delivery reviews.

[83]  Mauro Ferrari,et al.  Nanomedicine in cancer therapy: Innovative trends and prospects , 2011, Cancer science.

[84]  Yanjing Chen,et al.  Multicomponent folate-targeted magnetoliposomes: design, characterization, and cellular uptake. , 2011, Nanomedicine : nanotechnology, biology, and medicine.

[85]  Andreas Herrmann,et al.  Reduction-sensitive liposomes from a multifunctional lipid conjugate and natural phospholipids: reduction and release kinetics and cellular uptake. , 2011, Langmuir : the ACS journal of surfaces and colloids.

[86]  G. Stathopoulos,et al.  Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer , 2011, Cancer Chemotherapy and Pharmacology.

[87]  Wei Zhao,et al.  Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes , 2011, International journal of nanomedicine.

[88]  Andreas Wicki,et al.  Targeting Tumor-Associated Endothelial Cells: Anti-VEGFR2 Immunoliposomes Mediate Tumor Vessel Disruption and Inhibit Tumor Growth , 2011, Clinical Cancer Research.

[89]  Hu Liu,et al.  Novel tetrapeptide, RGDF, mediated tumor specific liposomal doxorubicin (DOX) preparations. , 2011, Molecular pharmaceutics.

[90]  J. Gubernator,et al.  Active methods of drug loading into liposomes: recent strategies for stable drug entrapment and increased in vivo activity , 2011, Expert opinion on drug delivery.

[91]  W. Denny,et al.  Targeting of nanoparticles in cancer: drug delivery and diagnostics , 2011, Anti-cancer drugs.

[92]  Fei Zhang,et al.  Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes , 2011, Journal of drug targeting.

[93]  Rajiv Chopra,et al.  Localised drug release using MRI-controlled focused ultrasound hyperthermia , 2011, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[94]  Kostas Kostarelos,et al.  Liposomes: from a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. , 2011, Accounts of chemical research.

[95]  J. Arias,et al.  Drug targeting strategies in cancer treatment: an overview. , 2011, Mini reviews in medicinal chemistry.

[96]  V. Torchilin,et al.  Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B , 2011, Journal of drug targeting.

[97]  V. Torchilin,et al.  Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting , 2011, Journal of drug targeting.

[98]  L. Gianni,et al.  Lipoplatin Treatment in Lung and Breast Cancer , 2010, Chemotherapy research and practice.

[99]  Junho Chung,et al.  Preparation and in vitro evaluation of anti-VCAM-1-Fab′-conjugated liposomes for the targeted delivery of the poorly water-soluble drug celecoxib , 2011, Journal of microencapsulation.

[100]  Azam Bolhassani,et al.  Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. , 2011, Biochimica et biophysica acta.

[101]  Sanjun Shi,et al.  Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes , 2011, International journal of nanomedicine.

[102]  Vladimir P Torchilin,et al.  Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[103]  K. Mann,et al.  Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. , 2012, Molecular pharmaceutics.

[104]  Nicholas A Peppas,et al.  Expert opinion: Responsive polymer nanoparticles in cancer therapy. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[105]  Y. Barenholz.  Doxil®--the first FDA-approved nano-drug: lessons learned. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[106]  H. Grüll,et al.  Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[107]  Neeraj Kumar,et al.  In Vivo Evaluation of Doxorubicin-Loaded (PEG)3-PLA Nanopolymersomes (PolyDoxSome) Using DMBA-Induced Mammary Carcinoma Rat Model and Comparison with Marketed LipoDox™ , 2012, Pharmaceutical Research.

[108]  Chengwen Sun,et al.  Grafting of cell-penetrating peptide to receptor-targeted liposomes improves their transfection efficiency and transport across blood-brain barrier model. , 2012, Journal of pharmaceutical sciences.

[109]  F. Kiessling,et al.  Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[110]  N. Düzgüneş,et al.  Genetic nanomedicine: gene delivery by targeted lipoplexes. , 2012, Methods in enzymology.

[111]  R. Bunte,et al.  Potent therapeutic activity of folate receptor-targeted liposomal carboplatin in the localized treatment of intraperitoneally grown human ovarian tumor xenograft , 2012, International journal of nanomedicine.

[112]  V. S. Lin,et al.  Chemically reducible lipid bilayer coated mesoporous silica nanoparticles demonstrating controlled release and HeLa and normal mouse liver cell biocompatibility and cellular internalization. , 2012, Molecular pharmaceutics.

[113]  Zhong Chen,et al.  Cyclic RGD peptide-modified liposomal drug delivery system: enhanced cellular uptake in vitro and improved pharmacokinetics in rats , 2012, International journal of nanomedicine.

[114]  Y. Maitani,et al.  Functional coating of liposomes using a folate– polymer conjugate to target folate receptors , 2012, International journal of nanomedicine.

[115]  R. Schiffelers,et al.  Design of cyclic RKKH peptide-conjugated PEG liposomes targeting the integrin α₂β₁ receptor. , 2012, International journal of pharmaceutics.

[116]  Vladimir P. Torchilin,et al.  Challenges in Development of Targeted Liposomal Therapeutics , 2012, The AAPS Journal.

[117]  K. Edwards,et al.  Nuclisome—targeting the tumor cell nucleus , 2012, Tumor Biology.

[118]  H. Maeda.  Macromolecular therapeutics in cancer treatment: the EPR effect and beyond. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[119]  H. Faneca,et al.  Folate-associated lipoplexes mediate efficient gene delivery and potent antitumoral activity in vitro and in vivo. , 2012, International journal of pharmaceutics.

[120]  V. Torchilin,et al.  Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[121]  Raj Kumar,et al.  Intracellular delivery of redox cycler-doxorubicin to the mitochondria of cancer cell by folate receptor targeted mitocancerotropic liposomes. , 2012, International journal of pharmaceutics.

[122]  Lin Zhu,et al.  Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. , 2012, ACS nano.

[123]  Vladimir P Torchilin,et al.  Increased apoptosis in cancer cells in vitro and in vivo by ceramides in transferrin-modified liposomes , 2012, Cancer biology & therapy.

[124]  T. Wirth,et al.  Pre-Targeting and Direct Immunotargeting of Liposomal Drug Carriers to Ovarian Carcinoma , 2012, PloS one.

[125]  Sadik Esener,et al.  Ultrasound mediated localized drug delivery. , 2012, Advances in experimental medicine and biology.

[126]  Eran Zahavy,et al.  Nano-Biotechnology for Biomedical and Diagnostic Research , 2012, Advances in Experimental Medicine and Biology.

[127]  J. Pedraz,et al.  Nanoparticle delivery systems for cancer therapy: advances in clinical and preclinical research , 2012, Clinical and Translational Oncology.

[128]  M. Büchert,et al.  Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  T. Boulikas,et al.  Lipoplatin Formulation Review Article , 2011, Journal of drug delivery.

[130]  J. Silverman,et al.  Marqibo® (vincristine sulfate liposome injection) improves the pharmacokinetics and pharmacodynamics of vincristine , 2012, Cancer Chemotherapy and Pharmacology.

[131]  Leaf Huang,et al.  Nanoparticle delivery of a peptide targeting EGFR signaling. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[132]  Lin Zhu,et al.  Stimulus-responsive nanopreparations for tumor targeting. , 2013, Integrative biology : quantitative biosciences from nano to macro.

[133]  Shyh-Dar Li,et al.  Hyperthermia-induced drug targeting , 2013, Expert opinion on drug delivery.

[134]  Vladimir P Torchilin,et al.  Bleomycin in octaarginine-modified fusogenic liposomes results in improved tumor growth inhibition. , 2013, Cancer letters.

[135]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[136]  Miqin Zhang,et al.  Superparamagnetic iron oxide nanoparticle-based delivery systems for biotherapeutics , 2013, Expert opinion on drug delivery.

[137]  V. Torchilin,et al.  Surface functionalization of doxorubicin-loaded liposomes with octa-arginine for enhanced anticancer activity. , 2013, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[138]  Vladimir P. Torchilin,et al.  Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting , 2013, Journal of drug delivery.

[139]  Eric C. Carnes,et al.  Mesoporous silica nanoparticle nanocarriers: biofunctionality and biocompatibility. , 2013, Accounts of chemical research.